The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.

Jing NiXianzhong ChengQian ZhaoZhiqin DaiXia XuWenwen GuoHongyuan GuRui ZhouYan WangXiaoxiang Chen

Published in: Journal of ovarian research (2021)

It is feasible that patients receiving a bolus of 200 mg/d in patients from Chinese population can acquire promising efficacy and tolerance. This is the first real-world data about niraparib in ovarian cancer patients with available HRD status from China.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
big data
patient reported outcomes
artificial intelligence